Comparative Pharmacology
Head-to-head clinical analysis: DESOXIMETASONE versus NUTRACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESOXIMETASONE versus NUTRACORT.
DESOXIMETASONE vs NUTRACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desoximetasone is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis. This leads to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Corticosteroid receptor agonist; induces anti-inflammatory proteins and suppresses inflammatory mediators.
Apply a thin film to affected skin areas twice daily.
One capsule (200 mg) orally twice daily with meals.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. Due to its topical use, systemic half-life is less clinically relevant; however, prolonged use on large areas or under occlusion may lead to systemic accumulation.
Clinical Note
moderateDesoximetasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Gatifloxacin."
Clinical Note
moderateDesoximetasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Rosoxacin."
Clinical Note
moderateDesoximetasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Levofloxacin."
Clinical Note
moderateTerminal half-life: 2-4 hours (mean 3 hours). Clinically, dosing every 6-8 hours maintains therapeutic levels.
Primarily renal (urinary) as inactive metabolites, with less than 5% unchanged drug. Fecal excretion accounts for a minor fraction, primarily via bile.
Renal (primarily as glucuronide and sulfate conjugates, <10% unchanged) and fecal (biliary excretion of metabolites). Approximately 70-80% renal, 20-30% fecal.
Category A/B
Category C
Topical Corticosteroid
Topical Corticosteroid
Desoximetasone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Trovafloxacin."